Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
about
Second-line chemotherapy in advanced and metastatic CRCCancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentTargeting the RAS oncogene.Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylationSecond-line systemic therapy for metastatic colorectal cancer.'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic ReviewPhase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumoursExposure-toxicity relationships for tipifarnib in cancer patientsGemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitorsTargeting protein prenylation for cancer therapyProtein Lipidation As a Regulator of Apoptotic Calcium Release: Relevance to Cancer.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis.Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agentsGenetic alterations in colorectal cancer.Lipid posttranslational modifications. Farnesyl transferase inhibitors.Fool's gold, lost treasures, and the randomized clinical trial.Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.The EML4-ALK oncogene: targeting an essential growth driver in human cancer.The emerging role of the RAB25 small GTPase in cancerPopulation pharmacokinetics of tipifarnib in healthy subjects and adult cancer patientsMolecular markers that predict response to colon cancer therapy.Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Tipifarnib: farnesyl transferase inhibition at a crossroads.Lonafarnib in cancer therapy.Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatmentThe new paradigm in the treatment of colorectal cancer: are we hitting the right target?Clinical activity of tipifarnib in hematologic malignancies.Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiationTargeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.Small molecule signal transduction inhibitors for the treatment of solid tumors.
P2860
Q24241235-09D39B3D-99AA-4534-8502-148C40975BF7Q26740619-FA54292B-D492-4F2F-8512-D52875A6FC75Q27687198-90561E7B-0BB0-4EF9-B167-77C44D77C24FQ28285888-9E7FDC4B-224C-4D1F-858D-3871216BDB12Q30238760-9B190092-6DEE-46E9-B0D3-FC4355F58726Q31125157-425E2ABC-358F-428D-A377-20B39E76462CQ33369069-5CEC3878-AC17-4346-AB9D-9D1628A9A94DQ33374647-BA55603A-9981-4D8E-B948-683623492A93Q33418889-57C2F2E0-BF15-4704-80CA-211371FCEBEFQ33644407-8A3AE089-E9A6-449F-9E63-10A8C07B9C14Q33669995-E2E71517-4D53-443A-B55C-3B30B9BD8105Q33679239-3F209F00-F615-437A-8C58-E7E55BAB80F0Q33849385-7C776821-F3A2-4C98-9F78-BC6EAE5E6840Q33914284-CD4F3F33-DA47-4A39-9EF8-C620A92BFF7CQ34052520-A5731939-01E9-4685-ADA3-9D5D666F7C1DQ34181861-83C781C5-59F1-49A6-8839-D8289C9A1134Q34457223-FBCD796C-8690-4099-BCC4-902410C6C96FQ34537580-EB16F945-829F-4553-9FE1-E9523112D0C3Q34609385-FFDE90B0-5674-4327-81CE-FCBF0378B3D2Q34638183-88EA1172-9595-4A41-9DCC-3E130E5B2FFBQ34651253-6E219E4A-F12B-4BE7-B1A5-BA725414E2EDQ34669260-9537CADA-0647-4F16-A508-21BC64B77877Q35044902-AD9F05CB-2F3D-4111-BA22-8AE98D29C76BQ35383553-B7D7DBA7-AB02-41F0-B97F-649CE7B00B25Q35525553-98E90BC2-F91F-4952-887A-DE309CD8CA9BQ35631006-12D02565-42E6-4CC4-8E60-AA912CEFB401Q35673314-B26AFA27-FDBA-48D3-BF53-3E2D823B3868Q35827635-690BD017-F8AF-4C13-9EBD-B854F8988556Q36150356-612760BB-6531-4C90-A087-3B4863EFE5CBQ36187034-6FB3E215-B0F3-4B83-8063-EA3EC0FA7286Q36217126-7432F643-4678-4D3B-98F1-5979ED51B8CAQ36398735-B1A6062A-CCB1-4478-A8DC-A96ED7423569Q36407429-669BA4E8-ADD6-4FFF-A8D7-1C20A583BD50Q36491847-14CB6E70-781B-425D-A8BB-19300FB88A16Q36609698-523E830A-BAC0-4CC4-8FC8-94A73D514250Q36736346-97E72D42-E98A-4FA5-A76C-CE322241D05FQ36736368-C842BEAA-DE43-446D-968B-606254518F3CQ36771749-38067BCD-E942-472D-BC8A-108B93C15C18Q36804407-DA4443D2-0469-44AF-841B-89AB1544F5B6Q36895413-C6FD270B-6347-454B-9776-87D702102E03
P2860
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Phase III double-blind placebo ...... ry advanced colorectal cancer.
@ast
Phase III double-blind placebo ...... ry advanced colorectal cancer.
@en
type
label
Phase III double-blind placebo ...... ry advanced colorectal cancer.
@ast
Phase III double-blind placebo ...... ry advanced colorectal cancer.
@en
prefLabel
Phase III double-blind placebo ...... ry advanced colorectal cancer.
@ast
Phase III double-blind placebo ...... ry advanced colorectal cancer.
@en
P2093
P356
P1476
Phase III double-blind placebo ...... ry advanced colorectal cancer.
@en
P2093
A de Gramont
G Kourteva
J Dostalova
J J Perez-Ruixo
P A Palmer
P304
P356
10.1200/JCO.2004.10.037
P407
P577
2004-10-01T00:00:00Z